Tag results:

type I diabetes

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type...

[vTv Therapeutics, Inc.] vTv Therapeutics Inc. announced positive results of a mechanistic study of TTP399 in patients with type 1 diabetes. The study demonstrated that patients with T1D taking TTP399 experienced no increase in ketone levels relative to placebo during a period of acute insulin withdrawal, indicating no increased risk of ketoacidosis.

The Healthy Exocrine Pancreas Contains Preproinsulin-Specific CD8 T Cells That Attack Islets in Type 1 Diabetes

[Science Advances] The authors quantified preproinsulin-specific CD8+ T cells within different areas of the human pancreas from nondiabetic controls, autoantibody-positive donors, and donors with type 1 diabetes to investigate their role in diabetes development.

Human Islet T Cells Are Highly Reactive to Preproinsulin in Type 1 Diabetes

[Proceedings of the National Academy of Sciences of the United States of America] Scientists comprehensively examined preproinsulin specificity of CD8 T cells obtained from pancreatic islets of organ donors with and without type 1 diabetes (T1D) and identified epitopes throughout the entire preproinsulin protein and defective ribosomal products derived from preproinsulin messenger RNA.

Biomaterial-Enabled Induction of Pancreatic-Specific Regulatory T Cells through Distinct Signal Transduction Pathways

[Drug Delivery and Translational Research] Scientists used poly (lactic-co-glycolide) to co-encapsulate type 1 diabetes-relevant antigen and 3 distinct TREG-inducing molecules - rapamycin, all-trans retinoic acid, and butyrate - that targeted the mechanistic target of Rapa, the retinoid pathway, and histone deacetylase inhibition, respectively.

Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, a Novel Therapy Designed to Address the Underlying Cause of...

[Precigen ActoBio] Precigen ActoBio, announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes.

Detecting Insulitis in Type 1 Diabetes with Ultrasound Phase-Change Contrast Agents

[Proceedings of the National Academy of Sciences of the United States of America] Researchers presented ultrasound imaging of nanodroplet (ND) contrast-agent accumulation within the islet. ND accumulation is dependent on immune infiltration; therefore, it tracked presymptomatic type I diabetes development and progression to diabetes

Popular